Incyte Bets $2 Billion on Vega Therapeutics to Secure Phase 3 Bleeding Disorder Monoclonal Antibody VGA039
On June 8, 2026, Incyte announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a transaction valued at up to $2 billion. The deal represents Incyte's largest strategic acquisition under CEO Bill Meury, aimed at diversifying its hematology portfolio and securing a major post-2029 revenue driver ahead of the 2028 patent cliff for its blockbuster drug Jakafi (ruxolitinib).
The Lead Asset: VGA039
The acquisition centers entirely on VGA039, a first-in-class monoclonal antibody currently in Phase 3 clinical development for von Willebrand disease (VWD), the most common inherited bleeding disorder:
"Vega Therapeutics, the Star subsidiary that Incyte is acquiring, began a phase 3 study of VGA039 in von Willebrand disease (VWD) in October. VGA039 is a monoclonal antibody that modulates the activity of Protein S (PS). By inhibiting PS without depleting the protein, VGA039 could increase the generation of a critical enzyme in the clotting process to restore hemostasis."
VWD patients are currently underserved and primarily rely on Takeda’s Vonvendi (a recombinant von Willebrand factor), which requires burdensome twice-weekly intravenous infusions for prophylactic treatment.
A "Hemlibra for VWD"
Incyte envisions VGA039 as a potential paradigm-shifting therapy, analogous to what Roche's blockbuster Hemlibra achieved in the hemophilia space. VGA039 offers a highly convenient subcutaneous route of administration and extended dosing intervals:
"VGA039 is administered subcutaneously and, based on phase 1/2 studies, can be given every four weeks. Vega reported a median bleed reduction of 81% in eight VWD patients in its early-phase program. The annualized bleeding rate dropped 75% and 100% in two patients who switched from intravenous prophylaxis to VGA039."
Incyte plans to target the estimated 7,000 to 10,000 VWD patients in the United States who suffer from severe, frequent bleeding and are currently eligible for intravenous prophylaxis.
Financial and Strategic Details
Under the terms of the agreement, Incyte will pay $1.25 billion upfront in cash, with up to $750 million in additional commercial and regulatory milestones, bringing the total deal value to $2 billion.
The ongoing Phase 3 trial of VGA039 is scheduled for completion in 2028. According to Meury, the drug is expected to be "highly accretive to sales and growth post '29, with approximately $1 billion or more in net sales potential." This timeline aligns perfectly with Incyte's need to offset the anticipated generic erosion of Jakafi starting in late 2028.